DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) gapped down before the market opened on Wednesday . The stock had previously closed at $19.09, but opened at $18.70. DICE Therapeutics shares last traded at $19.05, with a volume of 2,472 shares.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on DICE. Stifel Nicolaus started coverage on shares of DICE Therapeutics in a research report on Tuesday, September 6th. They set a "buy" rating and a $37.00 price objective on the stock. HC Wainwright started coverage on shares of DICE Therapeutics in a research note on Monday, July 18th. They set a "buy" rating and a $40.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on shares of DICE Therapeutics in a research note on Wednesday, September 14th. They set an "overweight" rating and a $36.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, DICE Therapeutics currently has a consensus rating of "Buy" and an average target price of $43.33.
Get
DICE Therapeutics alerts:
DICE Therapeutics Trading Down 2.0 %
The business has a fifty day moving average price of $18.47 and a two-hundred day moving average price of $17.73. The firm has a market capitalization of $701.17 million and a PE ratio of -4.80.
Institutional Investors Weigh In On DICE Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in DICE. Amalgamated Bank acquired a new position in DICE Therapeutics during the first quarter worth approximately $39,000. Prospera Financial Services Inc acquired a new position in DICE Therapeutics during the first quarter worth approximately $39,000. Legal & General Group Plc increased its position in DICE Therapeutics by 265.1% during the second quarter. Legal & General Group Plc now owns 4,764 shares of the company's stock worth $74,000 after buying an additional 3,459 shares during the period. Virtus ETF Advisers LLC increased its holdings in shares of DICE Therapeutics by 18.5% in the second quarter. Virtus ETF Advisers LLC now owns 7,482 shares of the company's stock valued at $116,000 after purchasing an additional 1,166 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of DICE Therapeutics in the second quarter valued at approximately $131,000. Institutional investors and hedge funds own 95.42% of the company's stock.
About DICE Therapeutics
(Get Rating)
DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.
Recommended Stories
- Get a free copy of the StockNews.com research report on DICE Therapeutics (DICE)
- What Steelcase's Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
